Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: News Direct
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.92
+3.63 (1.42%)
AAPL  336.67
+3.04 (0.91%)
AMD  645.86
-3.56 (-0.55%)
BAC  53.52
-0.57 (-1.05%)
GOOG  347.37
+2.78 (0.81%)
META  721.31
-17.57 (-2.38%)
MSFT  529.76
+0.46 (0.09%)
NVDA  237.47
-1.77 (-0.74%)
ORCL  143.56
-1.21 (-0.84%)
TSLA  377.81
-2.87 (-0.75%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.